Torley Helen's Form 4 filing
Halozyme Therapeutics, Inc. (HALO) · filed Oct 9, 2024
- Accession no.
- 0001415889-24-024936
- Filed
- Oct 9, 2024
- Trade date
- Oct 8-9, 2024
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Checked
This filing lists 7 non-derivative transactions and 2 derivative transactions. Open-market sales total $1.07M. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Torley HelenCIK 0001528185 | Director, Officer (PRESIDENT AND CEO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2024 | Common Stock | MOption exerciseAcquired | +10,000 | $13.87 | +$138,700 | 686,744 | Direct | |
| Oct 8, 2024 | Common Stock | SSaleDisposed | −9,100 | $53.94 | −$490,854 | 677,644 | Direct | |
| Oct 8, 2024 | Common Stock | SSaleDisposed | −900 | $54.57 | −$49,113 | 676,744 | Direct | |
| Oct 9, 2024 | Common Stock | MOption exerciseAcquired | +10,000 | $13.87 | +$138,700 | 686,744 | Direct | |
| Oct 9, 2024 | Common Stock | SSaleDisposed | −5,981 | $51.85 | −$310,114.85 | 680,763 | Direct | |
| Oct 9, 2024 | Common Stock | SSaleDisposed | −1,615 | $53.31 | −$86,095.65 | 679,148 | Direct | |
| Oct 9, 2024 | Common Stock | SSaleDisposed | −2,404 | $53.91 | −$129,599.64 | 676,744 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 8, 2024 | Common Stock | MOption exerciseDisposed | −10,000 | $13.87 | −$138,700 | 10,000 | Direct | |
| Oct 9, 2024 | Common Stock | MOption exerciseDisposed | −10,000 | $13.87 | −$138,700 | 0 | Direct |
Footnotes
Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.